INmune Bio, Inc.INMBNASDAQ
LOADING
|||
Year-over-year earnings per share growth rate
| Period | Value |
|---|---|
| Q3 2025 | 77.14% |
| Q2 2025 | -144.19% |
| Q1 2025 | -4.88% |
| Q4 2024 | 31.67% |
| Q3 2024 | -20.00% |
| Q2 2024 | 18.03% |
| Q1 2024 | -29.79% |
| Q4 2023 | 2.08% |
| Q3 2023 | -33.33% |
| Q2 2023 | 2.70% |
| Q1 2023 | -8.82% |
| Q4 2022 | 24.44% |
| Q3 2022 | -9.76% |
| Q2 2022 | 0.00% |
| Q1 2022 | 26.79% |
| Q4 2021 | -1.82% |
| Q3 2021 | -25.00% |
| Q2 2021 | -37.50% |
| Q1 2021 | -28.00% |
| Q4 2020 | 30.56% |
| Q3 2020 | -80.00% |
| Q2 2020 | -5.26% |
| Q1 2020 | 13.64% |
| Q4 2019 | 21.43% |
| Q3 2019 | -625.39% |
| Q2 2019 | 80.70% |
| Q1 2019 | -17.65% |
| Q4 2018 | -21.43% |
| Q3 2018 | 74.55% |
| Q2 2018 | -120.00% |
| Q1 2018 | -554.45% |
| Q4 2017 | -39.42% |
| Q3 2017 | 3.18% |
| Q2 2017 | -579.66% |
| Q1 2017 | 121.93% |
| Q4 2016 | -149.07% |
| Q3 2016 | 0.00% |